Drug interactions-

Anticonvulsants eg carbamazepine, phenobarbital, phenytoin ) + Etravirine-
coadmi n may cause a significant decrease of etravirine plasma concentration
and therapeutic effect.

Antifingals eg fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole
 + Etravirine/  Etrvirine + antifungals -
coadmin of fluconazole, itraconazole, ketoconazole, posaconazole with etravirine
may increase plasma concentration of etravirine. Plasma concentration of
itraconazole, or ketoconazole may be decreasd by ertavirine. Dose ajustments
of itraconazole, ketoconazole or voriconazole may be necessary

Atazanavir/ritinaavir + etravarine / etravarine + atazanavir-
concomttant use of etrvarine with atazanavir/ritonavir may cause a significant decrease
in atanavir

Darunavir/ritonavir + etravarine -
may be coadministered without adjustment

Dexamethasone + etravarine-
use with caution  or consider an alternative corticosteroid particularly if used for a long term
 

HIV infections

Adverse reactions-

Cardiovascular -  hypertension  2%

CNS - fatigue 3%   headache 2% peripheral neuropathy  2%

Dermatologic - rash 8%

GI -    abdominal pain  2%    diarrhea  5%  nausea 4%  vomiting 2%

Not known

Special precautions-
Skin - severe and potentially life threatening skin reactions have occured in patients taking
etravarine. If severe rash develops, discontinue treatment with etravarine and consider
alternate therapy

Renal function impairment - No dosage adjustment is reuired in patients with renal impairment.
Because etravarine is highly bound by plasma proteins it is unlilkely that it will significantly
removed by hemodialysis or peritonal dialysis.

Hepatic function impairment - no dosage adjustment of etravarine is required in patients
with mild or moderate hepatic function impairment

Pregnancy-use etravarine during pregnancy only if the potential benefit justifies the potential
risk to the fetus.

Lactation- instruct mothers not to breast feed if they are receiving etravarin

Children- safety and effectiveness in children not established

Elderly- dose selection in elderly patients should be cautious reflecting th greater freqency
of decreased hepatic, renal  or cardiac function and of concomitant disease or other drug
therapy.

Indication-
HIV infection

Dosage-
200mg ( two 100mg tablets ) taken twice daily following a meal . The type of food dose not
affect exposure of etravine

Patients who are unable to swallow etravine tablets may disperse the tablets in a glass of water.
Once dispersed patients should stir the dispersion well and drink immediately.
The glass should be rinsed completely and each rinse completely swallowed to ensure
that the entire dose is consumed

1. Inform patients that etravarine is not a cure for HIV infections.

2. Advice patients that etravarine dose not reduce the risk of passing HIV  infections through
   sexual contact. Advice patients to practice safe sex.

3. Advice patients to take etravarine following a meal twice a  day as prescribed

4. Patients who are unable to swallow etravine tablets may disperse the tablets in a glass
  of water.   Once dispersed patients should stir the dispersion well and drink immediately.
   The glass should be rinsed completely and each rinse completely swallowed to ensure
    that the entire dose is consumed

To taken following a meal

Pregnancy-
Use etravarine during pregnancy only if the potential benefit justifies the potential
risk to the fetus.

Lactation-
Instruct mothers not to breast feed if they are receiving etravarin

Children-
Safety and effectiveness in children not established

Elderly-
Dose selection in elderly patients should be cautious reflecting th greater freqency
of decreased hepatic, renal  or cardiac function and of concomitant disease or other drug
therapy.